Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SYRE 
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: SYRE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $54.29
1 Year Target Price $54.29
| 10 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.41% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.56B USD | Price to earnings Ratio - | 1Y Target Price 54.29 |
Price to earnings Ratio - | 1Y Target Price 54.29 | ||
Volume (30-day avg) 11 | Beta 3.15 | 52 Weeks Range 10.91 - 35.31 | Updated Date 12/25/2025 |
52 Weeks Range 10.91 - 35.31 | Updated Date 12/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.2% | Return on Equity (TTM) -38.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2410069896 | Price to Sales(TTM) 650.22 |
Enterprise Value 2410069896 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 77592130 | Shares Floating 67572658 |
Shares Outstanding 77592130 | Shares Floating 67572658 | ||
Percent Insiders 6.7 | Percent Institutions 84.3 |
Upturn AI SWOT
Spyre Therapeutics Inc.
Company Overview
History and Background
Spyre Therapeutics, Inc. was founded in 2022. The company is focused on developing and commercializing innovative therapies for autoimmune diseases. Significant milestones include its formation, early-stage research and development, and its initial public offering (IPO) which aimed to fund its pipeline. As a clinical-stage biopharmaceutical company, its evolution is characterized by progression through preclinical and clinical development stages.
Core Business Areas
- Autoimmune Disease Therapeutics: Spyre Therapeutics focuses on the discovery, development, and potential commercialization of novel biologic therapies for patients suffering from autoimmune diseases. This includes targeting specific pathways and molecules implicated in the pathogenesis of these conditions.
Leadership and Structure
The leadership team of Spyre Therapeutics includes experienced professionals in the biopharmaceutical industry, with expertise in drug development, clinical trials, and commercialization. The organizational structure is typical of a clinical-stage biopharmaceutical company, emphasizing research and development, regulatory affairs, and scientific leadership. Specific names of the leadership team can be found in company filings and investor relations materials.
Top Products and Market Share
Key Offerings
- SP-3101: SP-3101 is a potential first-in-class biologic therapy targeting IL-23 for the treatment of autoimmune diseases, including psoriasis and psoriatic arthritis. Market share data is not yet applicable as it is in clinical development. Key competitors in the IL-23 inhibitor space include AbbVie (Skyrizi), Janssen (Tremfya), and Eli Lilly (Taltz).
- SP-3102: SP-3102 is a novel antibody targeting CD11b for the treatment of autoimmune diseases. Market share data is not yet applicable as it is in clinical development. Competitors for CD11b-targeting therapies are less established, representing a potential first-mover advantage, but competition exists from other novel immunomodulatory agents in the autoimmune space.
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is a significant and growing segment of the pharmaceutical industry, driven by an increasing prevalence of autoimmune conditions, advancements in understanding disease mechanisms, and the development of targeted biologic therapies. The market is characterized by high R&D investment, long development cycles, and intense competition among established pharmaceutical companies and emerging biotechs.
Positioning
Spyre Therapeutics positions itself as a developer of novel, potentially best-in-class biologic therapies for autoimmune diseases. Its competitive advantage lies in its innovative approach to targeting specific disease pathways with its lead candidates, SP-3101 and SP-3102, aiming to offer improved efficacy and/or safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The total addressable market for autoimmune disease therapies is substantial, estimated in the tens of billions of dollars globally and projected to continue growing. Spyre Therapeutics is positioned to capture a segment of this TAM with its pipeline candidates, provided they achieve regulatory approval and demonstrate clinical differentiation. Its focus on specific autoimmune indications allows for targeted market penetration.
Upturn SWOT Analysis
Strengths
- Innovative pipeline targeting key pathways in autoimmune diseases.
- Experienced leadership team with biopharmaceutical expertise.
- Potential for first-in-class or best-in-class therapies.
- Strong initial funding through IPO.
Weaknesses
- Early-stage clinical development, facing significant clinical and regulatory risks.
- Limited commercialization track record as a relatively new company.
- Dependence on successful clinical trial outcomes.
- High cash burn rate associated with R&D activities.
Opportunities
- Growing demand for effective autoimmune disease treatments.
- Potential for strategic partnerships or acquisitions by larger pharmaceutical companies.
- Advancements in biotechnology enabling novel therapeutic approaches.
- Expansion into different autoimmune indications with pipeline candidates.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and stringent approval processes.
- Intense competition from established and emerging players.
- Pricing pressures and reimbursement challenges.
- Intellectual property challenges and patent expirations for competitors.
Competitors and Market Share
Key Competitors
- AbbVie (ABBV)
- Janssen (part of Johnson & Johnson) (JNJ)
- Eli Lilly and Company (LLY)
Competitive Landscape
Spyre Therapeutics faces a highly competitive landscape, particularly in the autoimmune disease market, where established players like AbbVie, Janssen, and Eli Lilly have significant market share with their existing biologic therapies. Spyre's advantage lies in its development of novel mechanisms and potentially differentiated profiles. However, it must overcome the substantial R&D and commercialization hurdles to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Spyre Therapeutics is largely characterized by its establishment and progression of its pipeline into clinical development. This includes R&D team expansion and strategic fundraising.
Future Projections: Future growth projections for Spyre Therapeutics are highly dependent on the successful clinical development and regulatory approval of its lead product candidates. Analyst projections would focus on potential peak sales of its pipeline drugs and market penetration. Success in clinical trials would be a significant driver of projected growth.
Recent Initiatives: Recent initiatives likely include advancing SP-3101 and SP-3102 into their respective clinical trial phases, building out the scientific and operational teams, and potentially exploring strategic collaborations or partnerships.
Summary
Spyre Therapeutics is a promising clinical-stage biopharmaceutical company with a focus on innovative autoimmune disease therapies. Its strengths lie in its novel pipeline and experienced leadership. However, it faces significant risks associated with clinical development and a highly competitive market. Careful navigation of regulatory pathways and successful trial outcomes are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC Form S-1, 10-K, 10-Q)
- Industry analysis reports
- Financial news outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and general industry knowledge, which may be subject to change. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 95 | Website https://www.spyre.com |
Full time employees 95 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.